BRISBANE, AUS, Aug 19, 2025 - (ACN Newswire) - Cholrem Pty Ltd, an Australian pharmaceutical research company, has published a landmark study inCardiology Research and Cardiovascular Medicine, revealing that its proprietary cyclodextrin-based therapy Cavadex reverses atherosclerotic cardiovascular disease (ASCVD), the world's leading cause of death.
Angiogram: Plaque Reduced Within 6 Weeks
The peer-reviewed case seriesdemonstrates rapid symptom relief and significant regression of arterial plaque, marking a potential paradigm shift in heart disease treatment. The study followed 20 high-risk patients with advanced angina, with 18 (90%) reporting substantial symptom improvement (P0.0001) compared to expected outcomes. Objective imaging confirmed unprecedented results, including Coronary Artery Calcium (CAC) score reductions (e.g., from 591 to 521) and a 70% coronary artery blockage reduced to 27%. Cavadex, formulated with 2-hydroxypropyl-β-cyclodextrin (HPβCD), stimulates the body's natural vascular repair, offering a faster, more effective approach than existing therapies.
The late Professor Laurie G. Howes, a renowned Australian cardiologist and study co-author, called Cavadex"the greatest pharmacological development in cardiology since statins."U.S. cardiologist Dr. James C. Roberts, who has treated hundreds with the therapy, noted,"We're seeing rapid, profound improvements in high-risk patients, with objective plaque regression and an excellent safety profile, leveraging a TGA- and FDA-approved molecule."
Cholrem, founded by Kyle Hodgetts - a heart disease patient who pioneered Cavadex after conventional treatments failed - has supplied over 20,000 units globally. Despite HPβCD's non-patentable status limiting industry investment, Cholrem is driving this breakthrough forward. The company urges global medical communities to launch large-scale trials to validate these findings for millions suffering from heart disease.
About Cholrem Pty Ltd: Cholrem is dedicated to advancing cyclodextrin-based therapies to combat ASCVD, the world's top killer, with a mission to deliver innovative, life-saving treatments.Cardiology Research and Cardiovascular MedicinePublished Paper:https://www.gavinpublishers.com/article/view/cyclodextrin-therapy-for-atherosclerotic-cardiovascular-disease-a-case-series-on-plaque-regression-and-symptomatic-improvement
Related Video
https://www.youtube.com/watch?v=5JqIanZxmuQ
Contact InformationKyle HodgettsCholrem Pty Ltd Founder & CEOinfo@cholrem.com+61 424830574
Related Videohttps://www.youtube.com/watch?v=5JqIanZxmuQ
SOURCE: Cholrem Pty Ltd
Copyright 2025 JCN Newswire. All rights reserved. www.jcnnewswire.com
Angiogram: Plaque Reduced Within 6 Weeks
The peer-reviewed case seriesdemonstrates rapid symptom relief and significant regression of arterial plaque, marking a potential paradigm shift in heart disease treatment. The study followed 20 high-risk patients with advanced angina, with 18 (90%) reporting substantial symptom improvement (P0.0001) compared to expected outcomes. Objective imaging confirmed unprecedented results, including Coronary Artery Calcium (CAC) score reductions (e.g., from 591 to 521) and a 70% coronary artery blockage reduced to 27%. Cavadex, formulated with 2-hydroxypropyl-β-cyclodextrin (HPβCD), stimulates the body's natural vascular repair, offering a faster, more effective approach than existing therapies.
The late Professor Laurie G. Howes, a renowned Australian cardiologist and study co-author, called Cavadex"the greatest pharmacological development in cardiology since statins."U.S. cardiologist Dr. James C. Roberts, who has treated hundreds with the therapy, noted,"We're seeing rapid, profound improvements in high-risk patients, with objective plaque regression and an excellent safety profile, leveraging a TGA- and FDA-approved molecule."
Cholrem, founded by Kyle Hodgetts - a heart disease patient who pioneered Cavadex after conventional treatments failed - has supplied over 20,000 units globally. Despite HPβCD's non-patentable status limiting industry investment, Cholrem is driving this breakthrough forward. The company urges global medical communities to launch large-scale trials to validate these findings for millions suffering from heart disease.
About Cholrem Pty Ltd: Cholrem is dedicated to advancing cyclodextrin-based therapies to combat ASCVD, the world's top killer, with a mission to deliver innovative, life-saving treatments.Cardiology Research and Cardiovascular MedicinePublished Paper:https://www.gavinpublishers.com/article/view/cyclodextrin-therapy-for-atherosclerotic-cardiovascular-disease-a-case-series-on-plaque-regression-and-symptomatic-improvement
Related Video
https://www.youtube.com/watch?v=5JqIanZxmuQ
Contact InformationKyle HodgettsCholrem Pty Ltd Founder & CEOinfo@cholrem.com+61 424830574
Related Videohttps://www.youtube.com/watch?v=5JqIanZxmuQ
SOURCE: Cholrem Pty Ltd
Copyright 2025 JCN Newswire. All rights reserved. www.jcnnewswire.com
編集部おすすめ
